SLC22A12 and gout: Other drugs with mild-to-moderate URAT1 inhibition activity, such as the lipid-lowering agent, fenofibrate, and the angiotensin receptor blocker, losartan, have been studied for the treatment of hyperuricemia and gout [32, 33], but there remains an important clinical need for potent and selective URAT1 inhibitors.